Roka Bioscience, Inc. (NASDAQ:ROKA) major shareholder Orbimed Advisors Llc sold 474,676 shares of the stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $0.72, for a total value of $341,766.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Orbimed Advisors Llc also recently made the following trade(s):

  • On Wednesday, September 27th, Orbimed Advisors Llc sold 127,601 shares of Roka Bioscience stock. The stock was sold at an average price of $0.98, for a total value of $125,048.98.
  • On Wednesday, August 23rd, Orbimed Advisors Llc sold 1,100 shares of Roka Bioscience stock. The stock was sold at an average price of $1.50, for a total value of $1,650.00.
  • On Thursday, August 24th, Orbimed Advisors Llc sold 14,300 shares of Roka Bioscience stock. The stock was sold at an average price of $1.50, for a total value of $21,450.00.
  • On Tuesday, August 22nd, Orbimed Advisors Llc sold 75,276 shares of Roka Bioscience stock. The stock was sold at an average price of $1.52, for a total value of $114,419.52.

Roka Bioscience, Inc. (NASDAQ ROKA) opened at 0.7594 on Thursday. The stock’s 50 day moving average price is $1.12 and its 200 day moving average price is $2.53. Roka Bioscience, Inc. has a 52-week low of $0.66 and a 52-week high of $8.50. The stock’s market capitalization is $3.80 million.

TRADEMARK VIOLATION WARNING: “Roka Bioscience, Inc. (ROKA) Major Shareholder Sells $341,766.72 in Stock” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/05/roka-bioscience-inc-roka-major-shareholder-sells-341766-72-in-stock.html.

An institutional investor recently raised its position in Roka Bioscience stock. Sabby Management LLC lifted its position in shares of Roka Bioscience, Inc. (NASDAQ:ROKA) by 6.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 389,136 shares of the medical research company’s stock after buying an additional 23,916 shares during the period. Sabby Management LLC owned approximately 7.77% of Roka Bioscience worth $1,374,000 as of its most recent SEC filing. 66.51% of the stock is currently owned by hedge funds and other institutional investors.

Roka Bioscience Company Profile

Roka Bioscience, Inc is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications.

Receive News & Stock Ratings for Roka Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roka Bioscience Inc. and related stocks with our FREE daily email newsletter.